| Patent | Date |
|---|
Clinical Regimen For Treating Myelodysplastic Syndrome With Phosphatase Inhibitor
App 20220184066 - LIST; ALAN F. ; et al. | 2022-06-16 |
Pathways for treating patients
Grant 11,361,867 - List , et al. June 14, 2 | 2022-06-14 |
TLR9-binding chimeric antigen receptors
Grant 11,286,306 - Abate-Daga , et al. March 29, 2 | 2022-03-29 |
Chimeric Antigen Receptors With Enhanced Tumor Infiltration
App 20220088073 - List; Alan F. ; et al. | 2022-03-24 |
Inflammasome activation in myelodysplastic syndromes
Grant 11,280,787 - List March 22, 2 | 2022-03-22 |
Companion Diagnostic For Combination Lenalidomide And Erythropoietin Treatment
App 20220040263 - List; Alan F. | 2022-02-10 |
Tlr9 Ligand Trap
App 20210253664 - Wei; Sheng ; et al. | 2021-08-19 |
Tetravalent Tlr9 Bispecific Antibody
App 20200354471 - LIST; ALAN F. ; et al. | 2020-11-12 |
S100A9 levels for predicting lenalidomide and erythropoietin responsiveness
Grant 10,697,970 - List | 2020-06-30 |
Inflammasome Activation In Myelodysplastic Syndromes
App 20200150118 - List; Alan F. | 2020-05-14 |
Soluble Cd33 For Treating Myelodysplastic Syndromes (mds)
App 20200055916 - List; Alan F. ; et al. | 2020-02-20 |
Inflammasome activation in myelodysplastic syndromes
Grant 10,488,411 - List Nov | 2019-11-26 |
Tlr9-binding Chimeric Antigen Receptors
App 20190309086 - Abate-Daga; Daniel ; et al. | 2019-10-10 |
Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
Grant 10,434,100 - List , et al. O | 2019-10-08 |
Companion Diagnostic For Combination Lenalidomide And Erythropoietin Treatment
App 20190240290 - List; Alan F. | 2019-08-08 |
Soluble CD33 for treating myelodysplastic syndromes (MDS)
Grant 10,344,072 - List , et al. July 9, 2 | 2019-07-09 |
Tlr9 Targeted Cytotoxic Agents
App 20190167803 - List; Alan F. ; et al. | 2019-06-06 |
Clinical Regimen For Treating Myelodysplastic Syndrome With Phosphatase Inhibitor
App 20190111053 - List; Alan F. ; et al. | 2019-04-18 |
Protein Phosphatase 2a Inhibitors For Treating Myelodysplastic Syndromes
App 20190046525 - List; Alan F. ; et al. | 2019-02-14 |
S100a9 Levels For Predicting Lenalidomide And Erythropoietin Responsiveness
App 20180292411 - LIST; ALAN F. | 2018-10-11 |
Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
Grant 10,071,094 - List , et al. September 11, 2 | 2018-09-11 |
Inflammasome Activation In Myelodysplastic Syndromes
App 20180164311 - LIST; Alan F. | 2018-06-14 |
Protein Phosphatase 2a Inhibitors For Treating Myelodysplastic Syndromes
App 20170340628 - List; Alan F. ; et al. | 2017-11-30 |
Tlr9 Targeted Cytotoxic Agents
App 20170333565 - LIST; ALAN F. ; et al. | 2017-11-23 |
Tetravalent Tlr9 Bispecific Antibody
App 20170335009 - LIST; ALAN F. ; et al. | 2017-11-23 |
Protein Phosphatase 2a Inhibitors For Treating Myelodysplastic Syndromes
App 20170209434 - List; Alan F. ; et al. | 2017-07-27 |
Method of identifying myelodysplastic syndromes
Grant 9,487,776 - List , et al. November 8, 2 | 2016-11-08 |
Soluble Cd33 For Treating Myelodysplastic Syndromes (mds)
App 20160215038 - List; Alan F. ; et al. | 2016-07-28 |
Pathways For Treating Patients
App 20150324543 - LIST; Alan F. ; et al. | 2015-11-12 |
Method of Identifying Myelodysplastic Syndromes
App 20120316081 - List; Alan F. ; et al. | 2012-12-13 |
Methods of using aminothiols to promote hematopoietic progenitor cell growth
Grant 5,906,984 - Capizzi , et al. May 25, 1 | 1999-05-25 |
| 